JB Pharma is preferred pick due to aggressive growth focus, high return ratios, lean B/S & healthy FCF. It is outpacing industry growth. Strong performance from inorganic opportunities is boosting growth. Growth in margin accretive CDMO business expected to remain strong
Posts in category RJ Fan Club
KEC is well-placed to capitalize on the government’s thrust on capex (16-09-2023)
KEC is on the cusp of a major turnaround driven by stellar growth & margin recovery. It is the leader in T&D EPC with a market share of ~20-25%. It is well-placed to capitalize on the government’s thrust on capex. Order book is strong. Revenue visibility is robust
KEC is well-placed to capitalize on the government’s thrust on capex
Kilpest has huge growth potential. Buy for 43% upside potential (16-09-2023)
Kilpest's molecular diagnostics business is a niche segment with strong potential. Market size is Rs 300+cr with huge growth potential. It has 10%+ market share. Co is cash-rich (Rs 151 cr) & will earn FCF of Rs 69 cr over the next three years. It is at a discount of ~51% to average P/E ratio of peers. Buy for 43% upside…
Kilpest has huge growth potential. Buy for 43% upside potential
Astra Microwave Products is well poised for strong growth ahead (16-09-2023)
AMPL is well poised for strong growth ahead led by strong sector tailwinds. It has domain expertise, strong R&D & manufacturing capabilities. The order-book position is healthy with buoyant prospects & pipeline presents strong growth visibility. TP Rs 510
Astra Microwave Products is well poised for strong growth ahead
Five Star can become a formidable player with huge untapped opportunity of INR 22trn (10-09-2023)
Five Star has more than 2 decades lending experience in small business loans & become a formidable player. It is uniquely positioned to capture the largest pie of the huge untapped opportunity of INR 22trn. 37% AUM growth in FY23 reflects its agility and business resiliency
Five Star can become a formidable player with huge untapped opportunity of INR 22trn
Beta Drugs is one of the leading players in the domestic oncology space (09-09-2023)
BETA DRUGS is well placed to capitalise on growth opportunities in the oncology drugs segment. It has a healthy Balance Sheet. Average RoE in past three years is 24%. P/E ratio is 15x. Revenue/earnings CAGR of 26%/33% over FY23–26 is expected. TP is Rs 1325
Beta Drugs is one of the leading players in the domestic oncology space
Buy Lemon Tree Hotels for target price of Rs 140 (40% upside) (09-09-2023)
LTHL has leadership position in midscale hotels segment with ~19% market share. It is well poised to capitalize from impending uptick in the hospitality industry. Its new hotel Aurika is likely to be a key growth driver & crown jewel with 75% occupancy & 2x ARR. Buy for target price of Rs 140 (40% upside)
Buy Lemon Tree Hotels for target price of Rs 140 (40% upside)
Atarco acquisition is a win-win deal for Gokex (03-09-2023)
Atarco acquisition is a win-win deal for Gokex. it will gain duty free access to the US & European markets. The acquisition is at a reasonable valuation & EPS accretive. It has diversified its footprint, added new global brands & increased its production capacity in low-cost regions
Nifty is in short term downtrend (03-09-2023)
Stock Futures are at ATH indicating higher leveraged positions. Nifty is in short term downtrend, making lower tops & lower bottoms. It is below 20 & 50 day SMA. 14 week RSI oscillator too is in decline mode, suggesting scope for more downside in near term
Nifty is in short term downtrend (03-09-2023)
Stock Futures are at ATH indicating higher leveraged positions. Nifty is in short term downtrend, making lower tops & lower bottoms. It is below 20 & 50 day SMA. 14 week RSI oscillator too is in decline mode, suggesting scope for more downside in near term